Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bromocriptine Mesylate

FDA-approved product (capsule, oral), marketed as Bromocriptine Mesylate, Cycloset, Parlodel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Bromocriptine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Adenoma
  • Hyperprolactinemia
  • Hypogonadism
  • Infertility
  • Parkinson disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bromocriptine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bromocriptine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bromocriptine for Patients With Schizophrenia and Prediabetes

    NCT03575000 · start 2026-01-01

    Registered record
    Registry ID
    NCT03575000
    Conditions
    Schizophrenia; PreDiabetes
    Interventions
    Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2026-07-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; PreDiabetes
    InterventionBromocriptine
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

    NCT07124221 · start 2025-09-12

    Registered record
    Registry ID
    NCT07124221
    Conditions
    Hyperprolactinemia
    Interventions
    Cabergoline tablets; Bromocriptine mesylate tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-09-12
    Completion
    2026-12-30
    Enrolment
    382

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperprolactinemia
    InterventionCabergoline tablets; Bromocriptine mesylate tablets
    PhasePhase 3
    Registry statusRecruiting

  • Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma

    NCT06556186 · start 2024-10-01

    Registered record
    Registry ID
    NCT06556186
    Conditions
    Pituitary Tumor
    Interventions
    Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy; Bromocriptin 2.5mg, 2-3 times a day
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-10-01
    Completion
    2027-03-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Tumor
    InterventionTransnasal transsphenoidal pituitary lesion resection under neuroendoscopy; Bromocriptin 2.5mg, 2-3 times a day
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

    NCT05180773 · start 2022-07-27

    Registered record
    Registry ID
    NCT05180773
    Conditions
    Peripartum Cardiomyopathy, Postpartum
    Interventions
    Bromocriptine; Placebo; Guideline Directed Medical Therapy for Heart Failure (GDMT); Rivaroxaban; Second Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-07-27
    Completion
    2028-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripartum Cardiomyopathy, Postpartum
    InterventionBromocriptine; Placebo; Guideline Directed Medical Therapy for Heart Failure (GDMT); Rivaroxaban +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Psychobiological Mechanisms Underlying Chronic Pain

    NCT04674670 · start 2021-11-01

    Registered record
    Registry ID
    NCT04674670
    Conditions
    Fibromyalgia; Pain, Chronic; Chronic Pain, Widespread
    Interventions
    Bromocriptine Mesylate Capsules; Amisulpride 400 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-11-01
    Completion
    2023-07-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia; Pain, Chronic; Chronic Pain, Widespread
    InterventionBromocriptine Mesylate Capsules; Amisulpride 400 MG; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

    NCT04128683 · start 2020-10-20

    Registered record
    Registry ID
    NCT04128683
    Conditions
    Anorexia Nervosa
    Interventions
    amisulpride; bromocriptine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2025-01-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia Nervosa
    Interventionamisulpride; bromocriptine; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

    NCT05565976 · start 2020-08-01

    Registered record
    Registry ID
    NCT05565976
    Conditions
    Stroke, Ischemic; Mild Cognitive Impairment; Dementia, Vascular; Metabolic Syndrome
    Interventions
    Dapagliflozin 10mg Tab; Statins (Cardiovascular Agents); Platelet Antiaggregant; Antidiabetic
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2025-07-01
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke, Ischemic; Mild Cognitive Impairment; Dementia, Vascular; Metabolic Syndrome
    InterventionDapagliflozin 10mg Tab; Statins (Cardiovascular Agents); Platelet Antiaggregant; Antidiabetic
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

    NCT04413344 · start 2020-06-05

    Registered record
    Registry ID
    NCT04413344
    Conditions
    Familial Alzheimer Disease (FAD); PSEN1 Mutation
    Interventions
    Bromocriptine Mesilate; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2020-06-05
    Completion
    2021-11-24
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Alzheimer Disease (FAD); PSEN1 Mutation
    InterventionBromocriptine Mesilate; Placebos
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • PRolaCT - Three Prolactinoma RCTs

    NCT04107480 · start 2019-06-21

    Registered record
    Registry ID
    NCT04107480
    Conditions
    Prolactinoma; Prolactin-Producing Pituitary Tumor
    Interventions
    Endoscopic trans-sphenoidal adenoma resection; Dopamine Agonists
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-06-21
    Completion
    2026-03-31
    Enrolment
    880

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProlactinoma; Prolactin-Producing Pituitary Tumor
    InterventionEndoscopic trans-sphenoidal adenoma resection; Dopamine Agonists
    PhasePhase 4
    Registry statusUnknown

  • Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

    NCT04038749 · start 2019-06-16

    Registered record
    Registry ID
    NCT04038749
    Conditions
    Lactation Suppressed
    Interventions
    Bromocriptine; Cabergoline; Natural methods
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-06-16
    Completion
    2022-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactation Suppressed
    InterventionBromocriptine; Cabergoline; Natural methods
    PhaseNot applicable
    Registry statusUnknown

  • Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

    NCT04351126 · start 2019-04-01

    Registered record
    Registry ID
    NCT04351126
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Fludrocortisone 0.1 Milligrams (mg); Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2020-02-29
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionFludrocortisone 0.1 Milligrams (mg); Bromocriptine
    PhasePhase 2
    Registry statusCompleted

  • Acute Olanzapine and Lipid Response

    NCT04181385 · start 2019-01-01

    Registered record
    Registry ID
    NCT04181385
    Conditions
    Healthy
    Interventions
    Olanzapine 10 milligram; Bromocriptine 5 milligram; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2020-06-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOlanzapine 10 milligram; Bromocriptine 5 milligram; Placebo oral tablet
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury

    NCT03496545 · start 2018-11-30

    Registered record
    Registry ID
    NCT03496545
    Conditions
    Subarachnoid Hemorrhage; Subdural Hematoma; Traumatic Brain Injury; Ischemic Stroke; Fever; Intracerebral Hemorrhage
    Interventions
    Bromocriptine 5 MG; Acetaminophen 650 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-11-30
    Completion
    2019-11-02
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage; Subdural Hematoma; Traumatic Brain Injury; Ischemic Stroke +2 more
    InterventionBromocriptine 5 MG; Acetaminophen 650 MG
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

    NCT03714763 · start 2018-11-01

    Registered record
    Registry ID
    NCT03714763
    Conditions
    Pituitary Adenoma
    Interventions
    Drug treatment; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-11-01
    Completion
    2022-01-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Adenoma
    InterventionDrug treatment; Surgery
    PhaseNot applicable
    Registry statusUnknown

  • Dopamine Action on Metabolism in Relation to Genotype

    NCT03525002 · start 2018-05-03

    Registered record
    Registry ID
    NCT03525002
    Conditions
    Obesity
    Interventions
    Bromocriptine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-03
    Completion
    2024-08-14
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionBromocriptine; Placebo
    PhasePhase 2
    Registry statusCompleted